ACIP COVID-19 Vaccines Work Group

Dr. Beth Bell, Work Group Chair

December 11, 2020
Recent ACIP Emergency Meetings

- December 1st:
  - Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine
    Phase 1a: 1) Healthcare personnel and 2) residents of long-term care facilities

- November 23rd ACIP reviewed:
  - Evidence to Recommendation Framework:
    Public Health Problem, Resource Use, Equity, Values, Acceptability, and Feasibility
  - Phased Allocation of COVID-19 Vaccines
COVID-19 Work Group activities – November & December 2020

- COVID-19 Vaccine Work Group meets 1-2 times per week

- Topics covered since last ACIP meeting:
  - Safety and efficacy of Pfizer-BioNTech COVID-19 Vaccine
  - GRADE of Pfizer-BioNTech COVID-19 Vaccine
  - Discussion of the balance of benefits and possible harms related to Pfizer-BioNTech COVID-19 Vaccine
  - Additional discussions around Phase 1b & 1c populations
Today’s agenda

- Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine Development Program
  Dr. William Gruber (Pfizer)

- GRADE: Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine
  Dr. Julia Gargano (CDC)

- Work Group interpretation of evidence and next steps
  Dr. Sara Oliver (CDC)
Next Steps

- ACIP is scheduled to meet December 13
- If FDA has issued an Emergency Use Authorization for Pfizer-BioNTech COVID-19 vaccine, ACIP will vote on recommendations for use in the United States
Work group members

**ACIP members**
- Beth Bell (chair)
- Grace Lee
- Jose Romero
- Keipp Talbot

**Ex-officio/government members**
- FDA: Doran Fink, Rachel Zhang
- NIH: Chris Roberts
- IHS: Thomas Weiser, Jillian Doss-Walker
- DOD: Bryan Schumacher
- CMS: Jeff Kelman
- BARDA: Christine Oshansky
- HHS: David Kim

**CDC Co-leads**
- Kathleen Dooling
- Sara Oliver

**Liaisons**
- AAFP: Jonathan Temte
- AAP: Sean O’Leary
- ACOG: Denise Jamieson (primary), Laura Riley (alternate)
- ACP: Jason Goldman
- AGS: Ken Schmader
- AIM: Rob Shechter (primary), Jane Zucker (alternate)
- AMA: Sandra Fryhofer
- ANA: Kendra McMillan (primary), Ruth Francis (alternate)
- APhA: Michael Hogue
- ASTHO: Marcus Plescia
- CSTE: Susan Lett
- IDSA: Jeff Duchin (primary), Carol Baker (alternate)

**Liaisons, cont’d**
- NACCHO: Matt Zahn (primary), Jeff Duchin (alternate)
- NACI: Matthew Tunis (primary), Linlu Zhao (alternate)
- NFID: Bill Schaffner (primary), Marla Dalton (alternate)
- NMA: Oliver Brooks
- SHEA: Marci Drees

**Consultants**
- Ed Belongia (safety)
- Matthew Daley (safety)
- Kathy Kinlaw (ethics)
- Dayna Matthew (health equity)
- Kathleen Neuzil (vaccinology)
- Stanley Perlman (microbiology/immunology)
CDC participants

- Doug Campos-Outcalt
- Mary Chamberland
- Thomas Clark
- Amanda Cohn
- Jean Cox-Ganser
- Katie Curran
- Jonathan Duffy
- Anthony Fiore
- Mark Freedman
- Sue Gerber
- Jack Gersten
- Susan Goldstein
- Sam Graitcer
- Lisa Grohskopf
- Julia Gargano
- Rita Helfand
- Terri Hyde
- Tara Jatlaoui
- Cynthia Jorgensen
- Erin Kennedy
- Ram Koppaka
- Jessica MacNeil
- Mona Marin
- Sarah Mbaeyi
- Nancy McClung
- Lucy McNamara
- Rebecca Morgan
- Titilope Oduyebo
- Christina Ottis
- Anita Patel
- Janell Routh
- Stephanie Schrag
- Tom Shimabukuro
- Natalie Thornburg
- Jennifer Verani
- Megan Wallace
- Cindy Weinbaum
- Yon Yu
- Jane Zucker
Thank you!

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.